the aid library

LIST OPTIONS

Filter

4329

Strategic Plan of Action and Budget 2016 – 2025 for Elimination of Onchocerciasis in Africa

World Health Organization WHO African Prgramme for Onchocerciasis Control (2012) C_WHO

The Strategic Plan of Action and Budget 2016-2025 for the elimination of onchocerciasisin countries was prepared based on the above dlrective for the consideration of IAF 18.The vision of the plan of action is to eliminate onchocerciasis in 80 percent of Africancountries. Implementation of the plan ... more

WHO presence in countries, territories and areas: 2023 report

World Health Organisation (WHO) (2023) C_WHO

The 2023 Country Presence Report provides an overview of what WHO does in countries to advance towards the SDGs and implement GPW13, how we do it, with whom we work, and what is needed to overcome challenges for achieving results and impact in countries.

Accelerating anaemia reduction: a comprehensive framework for action

World Health Organisation (WHO) (2023) C_WHO

This document is an output of a WHO cross-programme initiative aiming to improve the prevention, diagnosis and management of anaemia and thereby accelerate reduction in its prevalence. It comes at an important time, midway through the era of the Sustainable Development Goals, when progress in reduci... more

WHO: 33 Years in Namibia

World Health Organisation (WHO) (2023) C_WHO

This publication is part of WHO 75th anniversary and aims to capture key successes in public health globally and in Namibia. It includes contributory messages from the Head of State, Prime Minister and the Minister of ... and Social Services. more

Supporting the routine use of evidence during the policy-making process: a WHO checklist

World Health Organisation (WHO) (2023) C_WHO

This checklist is for any organization or person supporting the routine use of evidence in the process of policy-making. Evidence-informed policy-making (EIPM) is essential for achieving the Sustainable Development Goals (SDGs) and universal health... more

Water safety plan manual: step-by-step risk management for drinking-water suppliers, 2nd ed

World Health Organisation (WHO) (2023) C_WHO

Safe drinking-water management must consider drinking-water quality, acceptability and quantity in the context of public health protection. In this manual, the term “safety” encompasses these three elements. Although the principles in this manua... more

Download (129)

View PDF (143)

Anuual Report 2022: Lesotho

World Health Organisation (WHO) (2023) C_WHO

This annual report gives an overview of WHO lesotho Country office's undertakings and achievements in the context of an extraordinary health emergency. As we walk another mile this year, may we embrace all lessonst leanred in the previous year, lear... more

Download (149)

View PDF (183)

Total fat intake for the prevention of unhealthy weight gain in adults and children: WHO guideline

World Health Organization WHO (2023) C_WHO

This guideline provides updated, evidence-informed guidance on the percentage of total fat in the diet to reduce the risk of unhealthy weight gain. This guideline is intended for a wide audience involved in the development, design and implementation of policies and programmes in nutrition and pub... more

Download (115)

View PDF (136)

Annual Report of the WHO Country Office in Zimbabwe, 2022

World Health Organisation (WHO) (2023) C_WHO

This report highlights the work of the World Health Organization (WHO) in Zimbabwe towards contributing to the triple billion targets in the context of the Sustainable Development Goals (SDGs

Download (136)

View PDF (109)

Sustainable financing: report of the Working Group - Report by the Director-General

Working Group on Sustainable Financing World Health Organization (WHO) (2022) CC

The Director-General has the honour to transmit to the Seventy-fifth World Health Assembly the report of the seventh meeting of the Working Group on Sustainable Financing, which met in a hybrid format, from 25 to 27 April 2022.

Download (103)

View PDF (118)

Draft Proposed programme budget 2022–2023: Building forward better

World Health Organization (WHO) World Health Organization (WHO) (2021) CC

The development of this draft Proposed programme budget 2022–2023 comes at a unique moment for WHO. The world is in the grip of the coronavirus disease (COVID-19) pandemic and faces health, social and economic consequences on an unprecedented scal... more

Download (174)

View PDF (312)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 10 August 2023

World Health Organization WHO (2023) C_WHO

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more

External Link

Tool for Promoting Culturally Safe Childbirth: Basic Manual

Pan American Health Organization PAHO (2023) CC

This manual and its Excel tool are under revision. The revised edition will be published soon.

Communicating about Vaccination-related Risks

World Health Organisation (WHO) (2023) C_WHO

This document seeks to help health communication professionals working on the topic of immunization more effectively communicate about Events Supposedly Attributed to Vaccination and Immunization (ESAVI) by building trust in National Immunization Pr... more

Download (214)

View PDF (194)

A Roadmap to combat postpartum haemorrhage between 2023 and 2030

World Health Organization WHO (2023) C_WHO

WHO today released its first roadmap to tackle postpartum haemorrhage (PPH) – defined as excessive bleeding after childbirth - which affects millions of women annually and is the world’s leading cause of maternal deaths. Despite being preventable and treatable, PPH results in around 70 000 de... more

Download (249)

View PDF (368)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 9 October 2023

World Health Organization WHO (2023) CC

Download (147)

View PDF (139)

WHO Guide to conducting programme reviews for HIV, viral hepatitis and sexually transmitted infections

World Health Organization WHO (2023) C_WHO

Sound periodic programme reviews provide opportunities for countries to objectively assess progress and take corrective action to sustain or get back on track towards achieving their medium and long-term programme goals. It reflects people’s diverse needs, enables efficient use of ... system resources and improves the predictability, sustainability and transparency of the programmes. This publication provides guidance to countries on how to perform programme reviews for HIV, viral hepatitis and sexually transmitted infections in this dynamic health sector context. The guidance encourages integrated reviews across health programmes for more efficient use of health system resources. The welfare of populations to be served must be at the centre of health programme reviews, with the overarching resolve to protect and promote health as a human right. This guidance is intended for use by all national partners, including health ministries, related ministries, civil society, affected communities and other stakeholders, for participatory and evidence-informed programme reviews. more

Download (289)

View PDF (385)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection (March 2024)

World Health Organization WHO (2024) C_WHO

Hepatitis B (HBV) infection is a major public health problem and cause of chronic liver disease. The 2024 HBV guidelines provide updated evidence-informed recommendations on key priority topics. These include expanded and simplified treatment cri... more

Global report on diabetes 1. Diabetes Mellitus – epidemiology. 2. Diabetes Mellitus – prevention and control. 3. Diabetes, Gestational. 4. Chronic Disease

World Health Organization WHO (2016) C_WHO

Diabetes is a serious, chronic disease that occurs either when the pancreas does not produce enough insulin (a hormone that regulates blood sugar, or glucose), or when the body cannot effectively use the insulin it produces. Diabetes is an important public ... problem, one of four priority noncommunicable diseases (NCDs) targeted for action by world leaders. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades. more